Merck (MRK) Non-Current Deferred Tax Liability (2009 - 2026)
Merck (MRK) posted quarterly Non-Current Deferred Tax Liability of $1.5 billion for Q1 2026, up 6.03% year-over-year from $1.4 billion in Q1 2025, and up 3.82% quarter-over-quarter from $1.4 billion in Q4 2025.
Merck (MRK) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability rose 6.03% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 6.03% YoY), while the FY2025 annual figure was $1.4 billion, up 3.75% from the prior year.
- Non-Current Deferred Tax Liability advanced to $1.5 billion in Q1 2026 per MRK's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.1 billion in Q1 2022 and bottomed at $864.0 million in Q3 2024.
- Historically, Non-Current Deferred Tax Liability has averaged $1.6 billion across 5 years, with a median of $1.4 billion in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 155.07% — and 2023, when it slumped 66.51%.
- Merck's Non-Current Deferred Tax Liability stood at $1.8 billion in 2022, then surged by 64.79% to $3.0 billion in 2023, then slumped by 53.11% to $1.4 billion in 2024, then rose by 3.75% to $1.4 billion in 2025, then gained by 3.82% to $1.5 billion in 2026.
- Business Quant data shows MRK's Non-Current Deferred Tax Liability at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.43 Bn |
| Jun 30, 2026 | 1.43 Bn |
| Mar 31, 2026 | 1.49 Bn |
| Mar 31, 2026 | 1.49 Bn |
| Dec 31, 2025 | 1.44 Bn |
| Dec 31, 2025 | 1.44 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Jun 30, 2025 | 1.43 Bn |
| Jun 30, 2025 | 1.43 Bn |
| Mar 31, 2025 | 1.41 Bn |
| Mar 31, 2025 | 1.41 Bn |
| Dec 31, 2024 | 1.39 Bn |
| Dec 31, 2024 | 1.39 Bn |
| Sep 30, 2024 | 864.00 Mn |
| Sep 30, 2024 | 864.00 Mn |
| Jun 30, 2024 | 876.00 Mn |
| Jun 30, 2024 | 876.00 Mn |
| Mar 31, 2024 | 922.00 Mn |
| Mar 31, 2024 | 922.00 Mn |